COMPANY
Starlight Therapeutics
Timeline
- Trial start 1: A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression source ↗
Upcoming milestones
- May 1, 2027 (ESTIMATED) · 1 · A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression · NCT07431216
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07431216 | A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression | 1 | Not yet recruiting | May 1, 2026 | May 1, 2027 (estimated) |